The restructuring concentrates aTyr’s resources on a new late-stage study in patients with restrictive lung disease after its first Phase III trial missed its primary endpoint.

The Series B financing gives Crystalys additional capital to progress its late-stage clinical programme and prepare dotinurad for potential commercialisation.

Sacituzumab tirumotecan plus Keytruda improves progression-free survival in advanced NSCLC, expanding potential role of ADC-immunotherapy combinations.

The setback clouds expansion plans for the RNA-targeted therapy after a pivotal cardiovascular outcomes study failed to demonstrate a significant benefit in patients with transthyretin amyloid cardiomyopathy.

The collaboration will integrate manufacturing, clinical research, and commercial readiness services to support late-stage development of a next-generation mRNA therapy.

Funding will support the global SURPASS-IPF trial comparing deupirfenidone directly against standard-of-care pirfenidone in idiopathic pulmonary fibrosis.

The move comes just days after a multi-billion dollar partnership with Regeneron, signalling strong investor appetite for next-generation intracellular targeting platforms.